Dublin – Shares in Combigene AB, a little-known Swedish gene therapy firm, surged upward by 172% Oct. 12 on news of a preclinical licensing deal in epilepsy with Spark Therapeutics, which is potentially worth $328.5 million.
A study led by scientists at the Korean Research Institute of BioScience and Biotechnology in Daejeon is the first to demonstrate that Dilp8/INSL3-Lgr3/8-NUCB, neuropeptide y signaling may be a potential therapeutic target in cancer anorexia and cachexia, which is associated with increased cancer mortality.
